Multidrug-resistant tuberculosis (MDR-TB)

A course of treatment for uncomplicated tuberculosis (TB) takes a minimum of six months. When patients are resistant to the two most powerful first-line antibiotics (isoniazid and rifampicin), they are considered to have multidrug-resistant TB (MDR-TB).

MDR-TB is not impossible to treat, but the drug regimen is arduous, taking up to two years and causing many side effects.

Extensively drug-resistant tuberculosis (XDR-TB) is identified when patients show resistance to the second-line drugs administered for MDR-TB. The treatment options for XDR-TB are very limited. Two new drugs – bedaquiline and delamanid – have recently become available to some patients who have no other treatment options left.

In 2015 MSF treated 18,100 patients for TB, of whom 2,000 for MDR-TB.

For more information, please see tuberculosis.

Updates
The paediatric TB project in Dushanbe starts its first patient on a new treatment, and more about...
Gallery
South Africa has one of the highest burdens of Tuberculosis (TB) and (Drug Resistant) DR-TB in the...
Press release
“The lack of solid data and evidence on the safety and efficacy of the new TB drugs means that only...
Patient story
"I'm happy I got this treatment, because I couldn't even walk back then," she says, "but if I see...
Testimony
“These new drugs are really the last life-line for patients who have ran out of all other options”...
Gallery
MSF is one of the biggest non-governmental providers of tuberculosis (TB) treatment – including for...
Georgia
Tuberculosis (TB) is a major challenge in Georgia, with many people suffering from multi-drug...
Updates
“The intensification and proximity of fighting is clearly limiting access to the hospital,” said...
Op-ed
"The recommendations within the new WHO TB guidelines represent an opportunity for countries to...
Press release
MSF urges Indian Prime Minister not to cave to pressure from EU to accept trade deal that could...
Press release
“TB is curable, yet it is now the infectious disease that kills the most people in the world,” said...
Kyrgyzstan
Kyrgyzstan has high rates of drug-resistant tuberculosis (DR-TB) and yet many people have...
Press release
"The price for delamanid needs to come down to an affordable level, and Otsuka should also register...
Press release
MSF appreciates Otsuka Pharmaceuticals’ donation of 400 treatments of a novel drug, delamanid,...
Report
Download the complete report (pdf) Geneva/Cape Town – Médecins Sans Frontières (MSF) and the...
Press release
“African leaders really should see this summit as an opportunity to work together with Prime...

Pages